Antares Pharma, Inc. has announced positive results of an auto-injector that delivers a rapid subcutaneous injection of methotrexate.
Last Thursday, Antares Pharma, Inc. announced positive results of a clinical study evaluating Vibex MTX, an auto-injector designed to deliver a rapid subcutaneous injection of methotrexate for treatment of rheumatoid arthritis (RA). In the study, Vibex MTX was compared with subcutaneous and intramuscular injection of methotrexate with a conventional needle and syringe. All three methods of delivery produced equivalent results and safety.
Vibex MTX is designed to allow RA patients to inject themselves with methotrexate reliably, comfortably, and conveniently. The apparatus is equipped with several measures to prevent accidental needle-sticks. The company aims to file a new drug application for Vibex MTX with the FDA in 2012.